Drug Trial Radar · NCT05960201
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in Invasive Lobular Carcinoma
Last checked: Nov 20, 2026Latest source record: Aug 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Aug 10, 2023
Primary completion
Aug 20, 2024
Study completion Aug 20, 2024
Sponsor
- Lead sponsor
- Asan Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to explore the diagnostic validity of \[18F\]FES PET/CT for the evaluation of axillary lymph node metastasis in patients with invasive lobular breast cancer having clinically suspected or confirmed axillary lymph node metastasis.
Conditions
- Carcinoma, Lobular
Interventions
[18F]fluoroestradiol (FES)Drug
F-18 FES 111\~222 MBq(megabecquerel) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patient based sensitivity, specificity, positive predictive and negative predictive values of a qualitative [18F]FES PET/CT assessment of axillary lymph node metastasisTime frame: 90-120 min
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.